
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TAPBPL CRISPR/Cas9 KO Plasmid (h) | sc-409990 | 20 µg | $397.00 | |||
TAPBPL HDR Plasmid (h) | sc-409990-HDR | 20 µg | $445.00 |
TAPBPL (TAP binding protein-like) encodes an endoplasmic reticulum–resident chaperone that modulates antigen presentation by interacting with the peptide-loading complex and influencing peptide editing for MHC class I molecules. By shaping the repertoire and stability of peptide–HLA class I complexes, TAPBPL contributes to proteostasis-linked immune surveillance and impacts how cells display intracellular antigens to CD8+ T cells. Altered TAPBPL expression or function has been associated with immune evasion phenotypes in tumors and with dysregulated antigen presentation in inflammatory settings. Its role at the interface of ER quality control and antigen processing makes TAPBPL relevant to studies of immunopeptidomics, interferon-responsive pathways, and cell-intrinsic immune regulation.
TAPBPL CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the TAPBPL gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the TAPBPL locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, TAPBPL HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined TAPBPL target site.
When co-transfected with TAPBPL CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the TAPBPL locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.